Mission Statement, Vision, & Core Values of ZIVO Bioscience, Inc. (ZIVO)

When you look past the biotech buzzwords and focus on the fundamentals, ZIVO Bioscience, Inc.'s (ZIVO) mission to commercialize proprietary algal strains for human and animal health faces a stark reality check: a nine-month 2025 net loss of nearly $6.88 million, despite Q3 revenue growth to $65,625. How does a company with a 'Quest for Optimal Health' and a commitment to transparency and execution navigate a stockholders' deficit of $(3.29 million) while simultaneously needing an estimated $6.0 million in funding over the next year to continue as a going concern (a term that means they might defintely run out of cash)? Are the core values strong enough to bridge that massive funding gap, or is the vision simply a long-shot bet on their algae having double the antioxidant activity of competitors?

ZIVO Bioscience, Inc. (ZIVO) Overview

You're looking for a clear picture of ZIVO Bioscience, Inc. (ZIVO), and the reality is you're dealing with a pure research and development (R&D) play in the biotech and agtech sectors. This company, formerly known as Health Enhancement Products, is focused on developing therapeutic and nutritional products from its proprietary algal cultures.

Their core value proposition is built on a platform of optimized freshwater algae strains, which they use to create plant-based, non-GMO (genetically modified organism), and antibiotic-free ingredients. This is a bet on the future of sustainable, natural health solutions.

• Animal Health: Feed ingredients to support immune response against bovine mastitis and boost productivity in poultry.
• Human Nutrition: Functional food ingredients aimed at promoting healthy cholesterol balance, immune system support, and joint health.

The company's dedication is to the study, development, and commercialization of these natural nutritional compounds and bioactive molecules. As of the latest filings, their sales remain minimal, reflecting their R&D stage. The trailing 12-month revenue as of September 30, 2025, was only about $209,000.

2025 Fiscal Year Financial Performance: A High-Risk R&D Profile

When you look at ZIVO Bioscience, Inc.'s financial results for the nine months ended September 30, 2025, you see the classic profile of a pre-commercial biotech company: minimal revenue and significant cash burn. Here's the quick math on their latest performance: Revenue for the nine months was $119,025, which is an improvement from the $67,220 reported for the same period a year prior. That's a good percentage gain, but the absolute dollar amount is still tiny.

The real story lies in the losses and liquidity. For the third quarter of 2025, the company reported a net loss of $1,033,056. For the first nine months of the year, the net loss totaled $6,884,474. This is a heavy burn rate, but to be fair, it's a significant reduction from the $11.78 million loss in the prior year's nine-month period. Still, the company's cash position is defintely a flashing red light.

What this estimate hides is the severe liquidity crunch. As of September 30, 2025, ZIVO Bioscience, Inc. had only $57,222 in cash against total liabilities of $3,846,055. Management itself has stated there is substantial doubt about the ability to continue as a going concern, estimating a need for about $6.0 million over the next 12 months just to fund basic operations.

ZIVO's Position in the Natural Health and Agtech Industries

The company is positioning itself at the convergence of two powerful, growing trends: consumer demand for natural products and regulatory pressure against antibiotic overuse in agriculture. ZIVO Bioscience, Inc. believes its proprietary algae platform puts it at the forefront of the human nutrition and animal health markets.

Their focus on natural antioxidant solutions and non-antibiotic animal feed formulations addresses one of agriculture's most pressing global challenges. They are building a business around affordability, sustainability, and adaptability, which are crucial factors for long-term success in the competitive nutraceutical and agtech spaces. This strategic focus is why they are a company to watch, even with the near-term financial risks.

If you want to dig deeper into the balance sheet and cash flow, you should read Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors to understand the full scope of their financial health.

ZIVO Bioscience, Inc. (ZIVO) Mission Statement

You're looking for the bedrock of ZIVO Bioscience, Inc. (ZIVO), the guiding principle that explains their strategy and spending. The company's mission, synthesized from their public commitments, is clear: to pioneer and commercialize scientifically validated, natural nutritional compounds and bioactive molecules from proprietary algae strains to solve global challenges in human and animal health, thereby creating lasting value for shareholders. This isn't just corporate fluff; it's the map for their R&D spending and commercial partnerships.

This mission is the lens through which you should view their financial health and market opportunities. It anchors their pivot from a pure R&D shop to a commercial licensor, and it directly relates to their current financial reality, which shows a trailing 12-month revenue of only $209K as of September 30, 2025, but a market capitalization of $45.4M as of November 7, 2025, indicating investors are pricing in future execution of this mission. The mission has three core components that drive everything they do.

You can see how this focus impacts their bottom line in our deeper dive: Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors

Core Component 1: Pioneering Scientifically Validated Natural Solutions

The first pillar is a deep commitment to rigorous science, which is defintely crucial when you are dealing with novel ingredients. ZIVO is dedicated to the study, development, and commercialization of natural compounds derived from its proprietary algal strains, meaning they don't just sell algae; they sell validated, bioactive ingredients. This focus on efficacy is what separates them from commodity players.

Here's a concrete example of their commitment to quality: an independent biochemical analysis, requested by a major prospective customer in 2025, showed their algae product had nearly double the activity of Superoxide Dismutase (SOD), a powerful antioxidant, compared to a competing algae-based product. That's a measurable, science-backed advantage. They are not just saying their product is good; they are proving it with data, which is essential for securing high-value licensing deals.

Their research and development efforts fall into two categories:

• Efficacy: Proving the beneficial effect on a target species.
• Compliance: Ensuring products are safe and consistent in quality.

Core Component 2: Solving Global Health and Agricultural Challenges

The second component maps their science to massive, urgent market needs, particularly in animal health. The mission is to address one of agriculture's most pressing global challenges: reducing antibiotic use without compromising animal productivity. This isn't a small niche; it's a global imperative driven by regulatory pressure and consumer demand for antibiotic-free products.

The market opportunity is huge. For example, ZIVO's product targeting coccidiosis in broiler chickens is aimed at a global poultry industry that spent an estimated $1.1 billion in 2024 on control methods, mostly using decades-old compounds. Their non-antibiotic solution is positioned perfectly to capture a share of this market, which is why they expected to finalize a licensing agreement with a global animal health company in the first quarter of 2025. The broader antibiotic-free livestock feed segment is forecasted to grow at an exceptional 8.2% CAGR to reach $8.9 billion by 2033.

Their commitment to sustainability is also part of this challenge. The ZIVO algae strain absorbs roughly one pound of carbon dioxide to produce one pound of quality protein, showing a clear path to a sustainable, non-GMO, and antibiotic-free protein source.

Core Component 3: Creating Lasting Value for Shareholders

The final, and perhaps most critical, element for investors is the commitment to execution and delivering exceptional shareholder value. A great mission means nothing without a commercialization strategy, and ZIVO is focused on translating its intellectual property (IP) into revenue through licensing and product sales.

Their strategy is to pursue near-term markets-nutritional products and ingredients for human and animal applications-while building the foundation for longer-term medicinal and pharmaceutical opportunities. This means getting product out the door. The company's plan to complete the build-out at Alimenta Algae in late 2025, with the capability to produce roughly 100,000 kg per year, is a direct, measurable step toward commercial scale and increased revenue. This production capacity is what will support the new product commitments they expect to drive significant near-term growth in the nutraceutical market.

ZIVO Bioscience, Inc. (ZIVO) Vision Statement

You're looking at ZIVO Bioscience, Inc. (ZIVO) and trying to map their ambitious R&D (research and development) vision to their current financial reality. The direct takeaway is that their vision-a quest for optimal health through proprietary algae-is sound, but the near-term execution is a race against a very short cash runway.

Their vision isn't a single, flowery sentence; it's a strategic dual-path: commercializing natural nutritional compounds in the near-term while building a foundation for complex, long-term pharmaceutical applications. This approach is smart, but it demands immediate, profitable product commitments to overcome significant liquidity challenges.

A Quest for Optimal Health: The Dual-Market Focus

The core of ZIVO's vision is to deliver safe, effective, and science-backed natural solutions, which they call a 'Quest for Optimal Health.' This translates into a clear, two-pronged market strategy: human nutrition and animal health. They are leveraging their proprietary algal strains to address major global challenges, like reducing antibiotic dependence in agriculture. This is a huge, urgent market.

The near-term focus is the nutraceutical market, where they've already demonstrated a significant edge. Independent analysis showed their algae had nearly double the activity of Superoxide Dismutase (SOD), a key antioxidant, compared to a competitor. This breakthrough is the engine for their anticipated near-term growth from new product commitments. The market is ready for this, but the company's financial footing is not. For the nine months ended September 30, 2025, ZIVO reported revenue of only $0.119025 million, against a net loss of $6.88 million.

• Near-Term Win: Nutraceuticals (human and animal supplements).
• Long-Term Goal: Medicinal and pharmaceutical applications.

Core Values: Affordability, Sustainability, and Adaptability

ZIVO's operational philosophy is built on three pillars: affordability, sustainability, and adaptability. This isn't just marketing; it's a commitment to a cost-efficient production model. They avoid complex, expensive fermentation systems for their proprietary algae in favor of a simpler, covered, shallow pond model. This is key, because it lowers the barrier to entry and makes their product platform-plant-based, non-GMO, and antibiotic-free-truly scalable.

Their commitment to rigorous scientific testing and regulatory compliance is also a core value, which is defintely necessary when dealing with the FDA (Food and Drug Administration) and USDA (United States Department of Agriculture). But, still, the market is skeptical. As of November 7, 2025, ZIVO's market capitalization was around $45.4 million, which suggests investors are pricing in a high degree of execution risk. You can dig deeper into the numbers here: Breaking Down ZIVO Bioscience, Inc. (ZIVO) Financial Health: Key Insights for Investors

Mapping Near-Term Risks to Actionable Opportunities

The biggest risk is liquidity. As of June 30, 2025, ZIVO's cash balance was extremely low at only $9,823, and they have 'less than 1 year of cash runway.' Here's the quick math: with a trailing 12-month revenue of just $209K as of September 30, 2025, and a high burn rate, the company must close commercial agreements fast.

The opportunity, however, is clear. The animal health sector, specifically poultry, presents an exceptional near-term opportunity. The global poultry vaccines market alone is projected to reach $4.2 billion by 2032. ZIVO's data in chickens has been successful, pointing to a path for their algae culture to be a critical non-antibiotic feed ingredient.

This is a classic biotech scenario: a compelling, validated technology with a short fuse on the balance sheet. The immediate action for management is to convert those 'compelling commercial terms being negotiated' into signed contracts and cash flow.

Action: Management: Announce a major commercial partnership with a clear revenue timeline before year-end.

ZIVO Bioscience, Inc. (ZIVO) Core Values

You're looking for the bedrock of ZIVO Bioscience, Inc.'s strategy-what truly drives their decisions in the biotech and agtech space. The core values aren't just posters on a wall; they are the filter for their R&D spending and their commercialization efforts. For a company in the pre-revenue phase, these values map directly to their survival and long-term potential, especially when facing a 'going concern' warning.

Their mission is clear: a quest for optimal health, dedicated to developing and commercializing natural nutritional compounds and bioactive molecules from proprietary algal strains. This focus is what guides their work in human and animal health. You can read more about their history and business model here: ZIVO Bioscience, Inc. (ZIVO): History, Ownership, Mission, How It Works & Makes Money.

Scientific Innovation & Breakthrough Validation

The first core value is a relentless pursuit of scientific innovation, which they translate into validated, superior product performance. In the R&D world, you have to prove your claims, and ZIVO Bioscience has made this a priority in 2025. They are a research and development company, and that's where the majority of their capital is burned.

Here's the quick math on that commitment: for the first nine months of 2025, ZIVO Bioscience reported a net loss of approximately $(6,884,474), which is the cost of funding that research and development engine. That's a massive investment for a company with only $119,025 in revenue during the same period.

• Validate product performance with third parties.
• Focus on proprietary algal strains for unique compounds.
• Secure intellectual property (IP) for long-term protection.

A concrete example of this value in action came from an independent biochemical analysis in 2025. This study demonstrated that their proprietary algae had, on average, nearly double the activity of Superoxide Dismutase (SOD)-a critical antioxidant-compared to a competing algae-based product. That kind of breakthrough validation is what attracts major industry partners, and it defintely sets them apart in the nutraceutical marketplace.

Sustainable Health Solutions & Antibiotic-Free Focus

The second value is a commitment to developing sustainable, natural solutions that address urgent global health and agricultural challenges. This is where their biotech and agtech focus converges, targeting the massive market shift away from prophylactic antibiotics in livestock.

This value is driven by the market opportunity: the antibiotic-free livestock feed segment was valued at $4.5 billion in 2024 and is forecasted to reach $8.9 billion by 2033. ZIVO Bioscience is positioning itself at the center of this transformation. Their products are designed to be non-GMO, antibiotic-free, and a sustainable source of protein, fiber, and micronutrients.

Specific initiatives demonstrating this commitment include:

• Developing a feed ingredient for dairy cows to promote a healthy immune response to bovine mastitis, a costly industry problem.
• Formulating products for poultry to boost productivity and digestive efficiency, capitalizing on the high-growth poultry market.
• Targeting human applications like functional food ingredients to support joint health and immune modulation.

They are trying to solve a global problem at cost parity. That's a huge lift.

Transparency & Shareholder Commitment

For a publicly held company, especially one with a stockholders' deficit of approximately $(3,286,603) as of September 30, 2025, transparency and a clear commitment to shareholder value are paramount. This value is about honest communication and aligning management's interests with the investors'.

The leadership team has been very direct about their liquidity challenges, stating there is 'substantial doubt' about their ability to continue as a going concern without additional funding, estimating they need about $6.0 million over the next 12 months. This is tough news, but it's the kind of realism investors need.

They back up their conviction with action. Over the past year, both the Board and management have personally invested in the Company, which is a powerful signal of their deep conviction in the technology and strategy. Also, in 2025, they successfully raised funds through private equity and debt, including issuing a $250,000 convertible note to fund operations. They are using every tool to bridge the gap between their current cash of $57,222 and their long-term vision.